Virtual Hot Seat™: How the Experts Treat HER2+ Breast Cancer Across Lines of Care

Release Date: May 25, 2021
Expiration Date: May 25, 2022

Activity Overview

The use of adjuvant HER2-targeted therapy has dramatically improved outcomes for patients with early-stage HER2+ breast cancer. More recently, dual targeting, extended therapy, and adjuvant treatment of patients with residual disease following neoadjuvant therapy have further improved survival in the early-stage setting. Advances in the metastatic setting and the availability of effective regimens have now extended median overall survival times to nearly 5 years. Recent phase 3 data have led to the approval and introduction of a new antibody-drug conjugate and a regulatory submission for a tyrosine kinase inhibitor (TKI)-based regimen for patients with previously treated disease, further improving the outcome for patients diagnosed with HER2+ breast cancer.

This online, on-demand, case-based, CME-certified webcast brings together renowned experts in the treatment of HER2+ breast cancer. The format is an interactive, game-style, live webcast designed to aid clinicians in assessing the wealth of emerging data in treating HER2+ breast cancer, choosing appropriate treatment based upon patient and disease characteristics, and applying novel management strategies to their practices to improve the care of patients across the disease continuum.
 
This educational activity is an archive of the live virtual webcast held on Thursday, May 13, 2021.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

Target Audience

This educational program is intended for medical oncologists and other oncology health care professionals involved in the treatment of breast cancer. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other health care professionals interested in the treatment of patients with breast cancer are also invited to participate.

Learning Objectives

Upon completion of this activity, participants will be able to:

• Determine individualized treatment strategies for patients with early-stage or advanced/metastatic HER2+ breast cancer based on current data and emerging evidence
• Assess the impact of emerging data as well as recent approvals on evolving standards of treatment for patients with HER2+ breast cancer brain metastases
• Discuss emerging evidence on investigational strategies for patients with HER2+ breast cancer as well as their potential implications
• Devise strategies to optimize treatment outcomes among patients who receive HER2-targeted therapy for breast cancer, including methods to mitigate the impact and manage treatment-related adverse events

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible entities.

Faculty

Sara A. Hurvitz, MD, FACP
Professor of Medicine
Director, Breast Cancer Clinical Trials Program
Division of Hematology-Oncology
David Geffen School of Medicine, UCLA
Medical Director, Clinical Research Unit
Jonsson Comprehensive Cancer Center
Santa Monica, CA

Disclosures: Grant/Research Support: Ambrx, Amgen, AstraZeneca, Arvinas, Bayer, Daiichi Sankyo, Dignitana, Eli Lilly and Company, Genentech/Roche, Gilead, GlaxoSmithKline, Immunomedics, MacroGenics, Novartis, OBI Pharma, Pfizer, Phoenix Molecular Designs, Pieris, Puma, Radius, Sanofi, Seagen, Zymeworks; Stock/Shareholder: NKMAX (me); Stocks (spouse, not me): Ideal Implant, ROMTech; Other: Eli Lilly and Company (travel 2019).

William J. Gradishar, MD, FASCO, FACP
Betsy Bramsen Professor of Breast Oncology & Professor of Medicine
Chief, Division of Hematology/Oncology
Director, Maggie Daley Center for Women's Cancer Care
Deputy Director, Clinical Network
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Northwestern University Feinberg School of Medicine
Chicago, IL

Disclosures: Grant/Research Support: Breast Cancer Research Foundation. Consultant: AstraZeneca, Immunomedics, Eli Lilly and Company, MacroGenics, Novartis, Seagen.

Mark D. Pegram, MD
Professor of Medical Oncology
Director, Clinical/Translational Research Unit
Associate Dean for Clinical Research Quality
Stanford University School of Medicine
Associate Director for Clinical Research
Stanford Cancer Institute
Stanford, CA

Disclosures: Consultant: AstraZeneca/Daiichi Sankyo, MacroGenics, Genentech/Roche, Seagen.

Sara M. Tolaney, MD, MPH
Associate Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA

Disclosures: Grant/Research Support: AstraZeneca, Bristol Myers Squibb, Cyclacel, Eisai, Eli Lilly and Company, Exelixis, Genentech/Roche, Immunomedics/Gilead, Merck, NanoString, Nektar, Novartis, Odonate, Pfizer, Sanofi, Seagen; Consultant: AstraZeneca, Athenex, Bristol Myers Squibb, Certara, CytomX, DSI, Eisai, Eli Lilly and Company, Ellipses, 4D Pharma, Genentech/Roche, Immunomedics/Gilead, Kyowa Kirin, Merck, Mersana, NanoString, Nektar, Novartis, Odonate, OncoPep, OncoSec, Pfizer, Puma, Sanofi, Seagen.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.